A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

• Status: RECRUITING
• Trial end date: 2034-10-23

Summary

This study will assess if adding sacituzumab tirumotecan with pembrolizumab after surgery is effective in treating NSCLC for participants not achieving pathological complete response. The primary hypothesis of this study is sacituzumab tirumotecan plus pembrolizumab is superior to pembrolizumab monotherapy with respect to disease free survival (DFS) as assessed by blinded independent central review (BICR).

• Phase: PHASE3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; pembrolizumab; Pemetrexed